The New England Journal of Medicine September 30, 1993

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

Diabetes Control and Complications Trial Research Group

Bottom Line

In patients with Type 1 diabetes, intensive insulin therapy targeting near-normal blood glucose levels significantly delayed the onset and slowed the progression of microvascular complications including retinopathy, nephropathy, and neuropathy, though it increased the risk of severe hypoglycemia.

Key Findings

1. In the primary-prevention cohort, intensive therapy reduced the adjusted mean risk for the development of retinopathy by 76% (95% CI, 62 to 85%) compared to conventional therapy [1.1].

2. In the secondary-intervention cohort, intensive therapy slowed the progression of retinopathy by 54% (95% CI, 39 to 66%) and reduced the development of proliferative or severe nonproliferative retinopathy by 47% (95% CI, 14 to 67%).

3. In the two cohorts combined, intensive therapy reduced the occurrence of microalbuminuria by 39% (95% CI, 21 to 52%) and clinical albuminuria by 54% (95% CI, 19 to 74%).

4. Intensive therapy reduced the development of clinical neuropathy by 60% (95% CI, 38 to 74%) across both cohorts combined.

5. The primary adverse event associated with intensive therapy was a two-to-threefold increase in the incidence of severe hypoglycemia.

Study Design

Design

RCT

Open-Label

Sample

1,441

Patients

Duration

6.5 yr

Median

Setting

Multicenter, US/Canada

Population 1,441 patients aged 13-39 with insulin-dependent diabetes mellitus (Type 1) for 1-15 years, divided into a primary-prevention cohort (no retinopathy, n=711) and a secondary-intervention cohort (mild-to-moderate retinopathy, n=730)

Intervention Intensive insulin therapy (three or more daily injections or an external insulin pump) with the goal of maintaining blood glucose concentrations close to the normal range

Comparator Conventional insulin therapy (one or two daily injections) with goals centered on clinical well-being rather than strict euglycemia

Outcome Development and progression of diabetic retinopathy

Study Limitations

• Intensive insulin therapy was associated with a two-to-threefold increased risk of severe hypoglycemia [1.1].

• Intensive therapy resulted in more significant weight gain compared to the conventional therapy group.

• The study population was restricted to highly motivated individuals with Type 1 diabetes between the ages of 13 and 39 without macrovascular disease, which limited immediate generalizability to older patients, those with comorbidities, or those with Type 2 diabetes.

• The open-label design was unavoidable due to the visibly different nature of the interventions, introducing potential bias.

• Intensive therapy demanded substantial patient education, specialized multidisciplinary diabetes care teams, and financial resources, complicating real-world clinical implementation at the time.

Clinical Significance

The DCCT revolutionized the management of Type 1 diabetes by definitively proving that tight glycemic control prevents or delays microvascular complications. It established strict glycemic targets as the standard of care, spurred the widespread adoption of self-monitoring of blood glucose and multidose insulin or pump regimens, and highlighted the importance of multidisciplinary care teams.

Historical Context

Prior to the DCCT, the 'glucose hypothesis'—the theory that hyperglycemia directly causes diabetic microvascular complications—was fiercely debated within the medical community. The trial conclusively ended this debate and was hailed as a monumental medical advance. Furthermore, its longitudinal follow-up study (EDIC) later demonstrated a 'metabolic memory' or 'legacy effect', showing that the early period of intensive glycemic control conferred durable, long-term cardiovascular and microvascular protection extending decades later.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

The DCCT demonstrated that intensive glycemic control prevents microvascular complications like retinopathy and nephropathy. Physiologically, how does chronic hyperglycemia cause these specific microvascular changes compared to macrovascular complications?

Key Response

Tests knowledge of the polyol pathway, accumulation of Advanced Glycation End-products (AGEs), and reactive oxygen species (ROS) causing endothelial damage in small vessels, differentiating this from atherosclerosis mechanisms in large vessels.

Resident

Given the DCCT finding of a threefold increased risk of severe hypoglycemia with intensive control, how do you practically balance HbA1c targets in a newly diagnosed 25-year-old with Type 1 Diabetes versus a 75-year-old with a history of hypoglycemic unawareness?

Key Response

Requires applying the study risk-benefit profile (microvascular benefit vs. hypoglycemia risk) to individualize glycemic targets according to patient age, comorbidities, life expectancy, and hypoglycemia vulnerability.

Fellow

The DCCT primarily focused on microvascular complications. How did the long-term observational follow-up (the EDIC study) recontextualize the impact of intensive early insulin therapy on macrovascular complications, and what physiological concept did this establish?

Key Response

Tests knowledge of metabolic memory or the legacy effect shown in EDIC, where early intensive control yielded long-term cardiovascular benefits even after HbA1c levels converged between the two groups later in life.

Attending

The DCCT was conducted before the advent of continuous glucose monitors (CGMs) and modern insulin analogs. How do these modern technologies alter the risk-benefit equation of intensive control established by the DCCT, specifically regarding the hypoglycemia barrier?

Key Response

Explores how modern tools (CGM, insulin pumps, hybrid closed-loop systems) allow for the microvascular benefits of intensive control seen in DCCT while significantly mitigating the severe hypoglycemia risk that was the major limiting factor in the original trial.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The DCCT utilized a primary prevention cohort (no baseline retinopathy) and a secondary intervention cohort (mild retinopathy). Methodologically, why was it crucial to stratify the trial this way rather than using a single heterogeneous cohort adjusted for baseline disease in multivariable analysis?

Key Response

Critiques the design choice to separate primary prevention from progression. This stratification ensures adequate power to detect distinct biological thresholds for initiating versus worsening damage and prevents confounding by different non-linear rates of progression based on baseline structural damage.

Journal Editor

As a reviewer of the original DCCT manuscript, how would you scrutinize the definition and adjudication of severe hypoglycemia, and what concerns might you raise regarding the unblinded nature of the intervention on reporting bias for this adverse event?

Key Response

Highlights the challenge of open-label trials where intensive group patients, testing glucose more often and knowing their intensive status, might report hypoglycemia differently, thus questioning the robustness of the primary safety endpoint assessment.

Guideline Committee

Current ADA guidelines recommend a general HbA1c target of less than 7.0% for most non-pregnant adults. How does the DCCT evidence curve for HbA1c versus complication risk justify this specific threshold rather than aiming for true normoglycemia (less than 6.0%)?

Key Response

The DCCT showed a continuous log-linear relationship between HbA1c and complications, but the absolute risk reduction diminishes below 7.0% while the risk of severe hypoglycemia rises exponentially, directly informing the ADA sweet spot recommendation.

Clinical Landscape

Noteworthy Related Trials

1998

UKPDS Trial

n = 3867 · Lancet

Tested

Intensive blood glucose control with sulfonylureas or insulin

Population

Newly diagnosed type 2 diabetes patients

Comparator

Conventional treatment primarily with diet

Endpoint

Any diabetes-related endpoint

Key result: Intensive blood-glucose control substantially decreased the risk of microvascular complications in patients with type 2 diabetes.

2005

EDIC Study

n = 1375 · NEJM

Tested

Long-term observational follow-up of prior intensive vs conventional therapy

Population

Type 1 diabetes patients previously enrolled in the DCCT

Comparator

Prior conventional therapy group

Endpoint

Cardiovascular events and microvascular complications

Key result: Intensive diabetes therapy during the DCCT reduced the risk of cardiovascular events by 42 percent during the long-term follow-up.

2008

ACCORD Trial

n = 10251 · NEJM

Tested

Intensive glycemic control targeting HbA1c below 6.0 percent

Population

Type 2 diabetes patients with high cardiovascular risk

Comparator

Standard glycemic control targeting HbA1c 7.0 to 7.9 percent

Endpoint

Nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes

Key result: Intensive therapy did not significantly reduce major cardiovascular events and was associated with increased all-cause mortality.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis